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Highlights 
 Adherent patients were more satisfied with medication information 
 Thirty-four percent of patients reported being non-adherent to antipsychotics 
 Non-adherent patients were significantly younger than adherent patients 
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Abstract 
This study evaluated the influence of attitudes and beliefs towards antipsychotics on 
adherence, and aimed to understand how satisfaction with information impacts adherence 
in first-episode psychosis. Fifty randomly selected out-patients attending the COAST Early 
Intervention service completed a survey comprised of the Selwood Compliance Scale, 
Beliefs about Medicines Questionnaire, and the Satisfaction with Information about 
Medicines Scale. Thirty-four percent of patients reported non-adherence to antipsychotic 
medication, and they were significantly younger than adherent patients. Adherent patients 
were more satisfied with medication information than non-adherent patients (65.7% and 
34.3% respectively), suggesting that providing better information about antipsychotics  may 
improve adherence. 
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1. Introduction 
When treating patients with a long term illness, outcome is determined largely by the 
effectiveness of the recommended treatment (García et al., 2016). In the case of prescribed 
medication, it is only of benefit to patients when it is taken (Byerly et al., 2007). Medication 
adherence is defined as the extent to which patient’s medication-taking matches that 
agreed with the prescriber (World Health Organisation, 2003), and is suggested to be 
problematic when treating psychosis patients (Lau et al., 2015). Whilst antipsychotic 
medication is deemed an efficacious treatment (Gray et al., 2007), attaining and maintaining 
adherence is difficult (Leclerc et al., 2015). 
Non-adherence rates among psychiatric patients are high (Haddad et al., 2014). For patients 
presenting with a first-episode of psychosis (FEP), existing data suggests 30-40% of patients 
become non-adherent within six months, rising to up to 50% at one year (Coldham et al., 
2002; Kamali et al., 2006). Consequences of non-adherence in FEP include higher relapse 
rates (Crespo-Facorro et al., 2011) and higher readmission rates (Robinson et al., 2002). As 
well as the personal costs to patients, a significant cost to society in terms of the financial 
burden also exists (Lafeuille et al., 2013). 
Research shows that medication attitudes and beliefs are the most significant factors in 
predicting non-adherence, however with regards to antipsychotic medication, the evidence 
is unclear (Mutsatsa et al., 2003; Segarra et al., 2012). A meta-analysis conducted by 
Richardson et al. (2013) suggested there is a small to moderate association between patient 
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attitude to medication and adherence in psychosis patients. However it is important to note 
that the some included studies recruited individuals in different stages of the illness, and 
using a mixture of different measures (including the Health Belief Model (Becker, 1974), and 
Drugs Attitude Inventory (Hogan et al., 1983)). Furthermore, attitude to medication was 
found to be a predictor of adherence in patients diagnosed with schizophrenia or 
schizoaffective disorder, with those having a more positive attitude being more adherent 
(Baloush-Kleinman et al., 2011). Lack of insight has also been associated with non-
adherence to medication (Segarra et al., 2012). Coldham et al. (2002) found that in 200 
individuals diagnosed with a first-episode of psychosis, insight levels at initial assessment 
and after one-year were lower in non-adherent patients than adherent ones. Similar 
findings were observed by Chan et al. (2014), who found that higher levels of insight were 
observed in medication adherent patients diagnosed with schizophrenia. Non-adherence to 
medication generally has also been linked to medication inefficacy (Steger et al., 2012) and 
inadequate information giving (AlHewiti, 2003).  
In relation to antipsychotic medication, a large proportion of patients reported 
dissatisfaction with the information received (Bowskill et al., 2007; Paton & Esop, 2005), 
especially regarding information about side-effects (Gray et al., 2005). In a survey of 69 
patients diagnosed with schizophrenia, almost half (46%) of patients reported not having 
been warned about the potential side-effects of antipsychotic medication (Gray et al., 
2005). Furthermore, experiencing side-effects was significantly associated with treatment 
dissatisfaction (Gray et al., 2005). 
The present study therefore aimed to evaluate the influence of attitudes and beliefs 
towards antipsychotics and self-reported adherence, and to understand how FEP patient’s 
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satisfaction with the information they received impacted upon self-reported adherence. 
Finally, we will evaluate whether side-effects frequently associated with antipsychotic 
medication have an impact on adherence 
 
2. Methods 
2.1. Study Setting & Participants  
Participants were randomly selected from COAST Early Intervention in psychosis service, 
South London and Maudsley NHS Foundation Trust (SLaM). Patients attending the 
outpatient clinic were approached by independent researchers. Fifty patients (representing 
20% of the caseload) were interviewed. Participants were required to be over 18 years old 
and have been prescribed antipsychotic medication. To improve the validity of self-report 
measurements, validated questionnaires were used, and participants were reassured that 
the data would not be shared with clinicians. The project was approved by SLaM NHS 
Foundation Trust (PSYAUD16/18).  
 
2.2. Procedure & Measures  
Self-reported adherence was measured with the Selwood Compliance Scale (Barrowclough 
et al., 1999), consisting of four statements regarding medication taking behaviour. Patients 
reporting “never missing a dose” were classified as adherent, and others as non-adherent. 
Beliefs about antipsychotics were assessed using the Beliefs about Medicines Questionnaire 
(BMQ) (Horne et al., 1999), BMQ-Specific examines patients’ beliefs about medication 
prescribed for personal use, using two subscales: Necessity and Concern. BMQ-General 
examines beliefs about medicines in general, using two subscales: Harm and Overuse. 
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Answers were scored on a 5-point Likert scale and a total score per BMQ scale was 
calculated. Adequacy of information received regarding prescribed medications was 
assessed using the Satisfaction with Information about Medicines Scale (SIMS) (Horne et al., 
2001). Patients reporting that the information was “about right” or “none needed” were 
classified as satisfied and the remainder were classified as dissatisfied. Participants were 
asked whether they were experiencing any medication side-effects, as well as their concerns 
about them. 
 
2.3. Data Analysis  
Data were analysed using SPSS 22 (IBM, Armonk, NY). Statistical tests were two-tailed 
(p=0.05). Continuous variables were compared using Student's t-tests, and categorical 
variables using Pearson's chi-square and Fisher's exact tests. To identify the main predictors 
of adherence to antipsychotics binary logistic regression was used. 
 
3. Results 
Fifty FEP patients participated, with a mean age of 28.4 years (SD=5.9), see table 1. Thirty 
two (64%) were male, with average contact with mental health services being 38.8 months 
(SD=55.9). Almost half of the sample was Black-British Caribbean/African/Other (48%), and 
were living with family (49%). In addition, 26 (52%) were unemployed, and 20 (40%) had 
above school qualifications. 
Overall, 66% were classified as adherent, and 34% as non-adherent to antipsychotics. 
Independent t-tests showed non-adherent patients were significantly younger than 
adherent ones (t(45)=2.09,p<0.05). No significant differences were found for gender, 
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ethnicity, living with family or unemployment (all p’s>0.05). Fishers exact test showed no 
statistically significant differences for medication type (p=0.24). 
One-way ANOVA’s compared the effects of BMQ Necessity, Concerns, Harm, and Overuse 
scales on adherence. A significant effect of BMQ Concerns (F(1,48)=8.73,p=0.005) and BMQ 
Harm (F(1,48)=7.27,p=0.010) was found on adherence. The model was significant 
(χ2(2)=14.4,p<0.001), correctly classifying 82% of cases. The variables inputted into the 
model included gender, age, BMQ Concern, Harm and Overuse subscales and SIMS scales. 
Age (β=0.169;p=0.026) and perceived concerns about antipsychotics (β=0.252;p=0.006) 
remained significant predictors of medication adherence. 
Adherent patients were generally more satisfied with all aspects of the information 
provided about medications than non-adherent ones (65.7% and 34.3% respectively). 
Specifically, in regards to the “risk of getting side-effects”, non-adherent patients were 
significantly less satisfied with the information received than adherent patients 
(χ2(1)=7.26,p<0.01)(Figure 1). 
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Figure 1: Satisfaction percentages among adherent and non-adherent patients. 
 
Fifty-two percent of the sample reported weight gain as the most common side-effect of 
antipsychotics, with 77% reporting feeling highly worried about it. A Fishers exact test 
showed no significant correlation between subjective worry about weight gain and 
adherence (p=0.056).  
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4. Discussion 
One third of patients receiving FEP treatment from the COAST Early Intervention service 
were found to be non-adherent to their prescribed antipsychotic medication. This is in 
accordance with research finding non-adherence rates in FEP patients to be between 33 and 
44% (Coldham et al., 2002; Kamali et al., 2006; Perkins et al., 2008). 
Our findings are in line with the Health Belief Model, which suggests that patients are more 
likely to adhere to medication if they believe the benefits will outweigh the costs (Becker, 
1974). In the present study, satisfaction with information in general was not significantly 
associated with non-adherence; however it is important to note that non-adherent patients 
were less satisfied with information received regarding the risk of having side-effects. This 
finding is concordant with previous research, suggesting that those who were non-adherent 
were less satisfied with the information they received compared to adherent patients 
(AlHewiti, 2003; Bowskill et al., 2007; Paton & Esop, 2005), therefore there is room for an 
intervention to improve this. The finding that non-adherent patients were significantly less 
satisfied with the information received about side-effects than adherent patients does 
support previous research (Gray et al., 2005). Further research could help determine 
whether increased information giving would increase satisfaction and adherence. This view 
is supported by NICE guidelines, which suggest an approach whereby information regarding 
medications is offered and potential side-effects/benefits discussed with the patient (NICE, 
2009). 
Weight gain was most prevalent side-effect reported, with patients reporting that they are 
highly concerned about it. Perceived concern about weight gain however was not found to 
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influence adherence. This finding is similar to a study which found that although 60% of 
patients reported weight gain as a side-effect, it was not related to missing medication 
(McCann et al., 2009). The high percentage of patients reporting weight gain and concern 
regarding this side-effect suggests that patients should be offered education early in 
treatment about side-effects, and perhaps signposting to services that could support weight 
loss efforts. 
This study involved a random sample of FEP patients treated in real-world conditions, 
utilising structured questionnaires to measure adherence & satisfaction. A further strength 
of our findings is the strength of the logistic model. In this study, adherent patients were 
successfully predicted with 82% accuracy. This suggests the model is a good fit to the data, 
and this may be in part due to the sample and the relevant variables included.  It should be 
noted that due to the cross-sectional design, conclusions about causality in this study 
cannot be drawn. Research indicates that patients who are less adherent are those who 
miss appointments (Sellwood et al., 2003), and are less likely to engage in research 
(Klingberg et al., 2008), therefore the sample used in the present study may not be 
generalisable to the wider FEP population. A further limitation is the use of a self-report 
measure of adherence, however they are the most common measure used throughout 
research (Velligan et al., 2006), are quick to administer, and are low cost (Stirratt et al., 
2015). 
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Table 1: Demographic characteristics of patients. 
Characteristic Total  
N=50 
Adherent  
N=33 (66%) 
Non-adherent 
N=17 (34%) 
P Value 
Age Mean (±SD) 28.43 (±5.9) 29.73 (±6.1) 26.12 (±5.0) 0.04 
Contact with mental health services 
(months) Mean (±SD) 
38.84 (55.9) 46 (±67.4) 24.94 (±12.9) 0.44 
Gender N(%) 
Male 
Female 
 
32 (64.0) 
18 (36) 
 
22 (66.7) 
11 (33.3) 
 
10 (58.8) 
7 (41.2) 
0.75 
Ethnicity N (%) 
Black British caribbean/african/other 
Other 
 
24 (48) 
26 (52) 
 
17 (51.5) 
16 (48.5) 
 
7 (41.2) 
10 (58.8) 
0.49 
Education level N (%) 
None 
School level 
University level 
Other 
 
5 (10.0) 
23 (46.0) 
20 (40.0) 
2 (4.0) 
 
3 (9.1) 
13 (39.4) 
15 (45.5) 
2 (6.0) 
 
2 (11.8) 
10 (58.8) 
5 (29.4) 
0 (0.0) 
0.43 
Living situation N (%) 
With family 
Without family 
 
24 (49) 
25(51) 
 
15 (46.9) 
17 (53.1) 
 
9 (58.8) 
8 (41.2) 
0.69 
Unemployed N (%) 26 (52.0) 20 (60.6) 6 (35.3) 0.09 
Medication Type N (%) 
Oral 
Depot 
 
42 (85.7) 
7 (14.3) 
 
28 (87.5) 
4 (12.5) 
 
14 (82.4) 
3 (17.6) 
0.62 
Remember medication name N (%) 
Yes 
No 
 
43 (86.0) 
7 (14.0) 
 
27 (81.8) 
6 (18.2) 
 
16 (94.1) 
1 (5.9) 
0.16 
 
